STEVEN JAY FRANK to Prostate-Specific Antigen
This is a "connection" page, showing publications STEVEN JAY FRANK has written about Prostate-Specific Antigen.
Connection Strength
1.283
-
Outcomes after prostate brachytherapy are even better than predicted. Cancer. 2012 Feb 01; 118(3):839-47.
Score: 0.285
-
A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol. 2020 08; 149:64-69.
Score: 0.131
-
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
Score: 0.110
-
Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun; 15(3):274-282.
Score: 0.098
-
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
Score: 0.078
-
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9.
Score: 0.074
-
Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):883-8.
Score: 0.069
-
Subacute penile numbness after brachytherapy for prostate cancer. Brachytherapy. 2011 Jan-Feb; 10(1):64-7.
Score: 0.067
-
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. J Clin Oncol. 2023 08 20; 41(24):4035-4044.
Score: 0.041
-
Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int. 2023 09; 132(3):307-313.
Score: 0.040
-
Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study. Radiother Oncol. 2023 06; 183:109599.
Score: 0.040
-
Evidence Based Strategies in the Management of Localized Prostate Cancer and the Role of Brachytherapy. S D Med. 2023 Jan; 76(1):16-23.
Score: 0.040
-
Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy. 2021 Nov-Dec; 20(6):1114-1129.
Score: 0.036
-
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
Score: 0.032
-
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):790-797.
Score: 0.030
-
ACR Appropriateness Criteria? Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
Score: 0.022
-
Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51.
Score: 0.021
-
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
Score: 0.019
-
American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy. 2011 Sep-Oct; 10(5):357-62.
Score: 0.018
-
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1310-7.
Score: 0.016
-
Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1433-8.
Score: 0.015